SRP-9003

Phase 3Biologic

Sarepta Therapeutics

SRP-9003 is one of 6 biologic programs targeting Muscular Dystrophy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Muscular DystrophyActive, not recruiting

Muscular DystrophyPhase 3

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Muscular Dystrophy

#DrugCompanyPhaseTrials

Cialis

Glucophage

Duvyzat

1 4

Glucocorticoid

AbbVie

Phase 3

1 5

SRP-9003

Sarepta Therapeutics

Phase 3

1 6

HB-Admscs

HHope Biosciences Research Foundation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 3Active, not recruiting

Muscular Dystrophy

NCT06246513

Clinical

Trials by Indication[1]

Muscular Dystrophy1 trial

A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4

Active, not recruiting· Sarepta Therapeutics logo

Sarepta Therapeutics·Phase 3·NCT06246513·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SRP-9003. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SRP-9003 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SRP-9003. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sarepta Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Sarepta Therapeutics

SRP-9003

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Muscular Dystrophy1 trial

References

Drug Info

Quick Facts

Related News